Hola,
Are you new here?

ActiTOX

financed

Active organotypic models for nanoparticle toxicological screening

Nanoparticles and new drugs are undergoing complex toxicity evaluation prior to their use in products for customers. However, the traditional pre-clinical testing protocols are delivering significant disadvantages both from ethica... see more

31/07/2024

Fraunhofer

1M€

Project Budget: 1M€

Project leader

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANG... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 10 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2024-07-31

MSCA-RISE-2018: Research and Innovation Staff Excha... Objective:The RISE scheme promotes international and cross-sector collaboration through exchanging r...

I+D

Cerrada does 7 years

0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

10 Participantes

Fraunhofer

188.60K€ | Leader

Inocure

96.60K€ | participant

OSPIN

55.20K€ | participant

TU WIEN

124.20K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 61 months Date Start: 2019-06-13
End date: 2024-07-31

Project leader

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANG... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 1M€

participation deadline Sin fecha límite de participación.

Project description Nanoparticles and new drugs are undergoing complex toxicity evaluation prior to their use in products for customers. However, the traditional pre-clinical testing protocols are delivering significant disadvantages both from ethical (animal testing) and functional (high attrition rate in clinical testing) point of view. ActiTOX reacts to this problem by the development of a novel, pre-clinical, high content, in vitro testing platform focused on the evaluation of nanoparticles/drugs via ADME (absorption, distribution, metabolism, excretion) toxicity studies. In order to advance the current state of art the project will employ biomimetic scaffolds, drug delivery systems, human induced pluripotent stem cells (iPSCs), 3D-microfluidics and modular bioreactor technology. ActiTOX aims to increase the relevance of in vitro studies and provide a scalable approach for their use in drug development and toxicological screening. In order to achieve the project goals, a training network enabling efficient short-term secondments of ER and ESR between academia and industry will be established. The cooperation between stakeholders helps closing the gap between them and oint innovation to foster the current state of the art. ActiTOX will mediate it via networking, research, training, workshop, innovation and dissemination actions in form of short-term secondments. The project fulfils the aim of a RISE project and delivers significant social impact, increases knowledge based economy and creates long lasting cooperation strengthening the European research area.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers